Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
about
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.A multi-targeted approach to treating bone metastases.Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.
P2860
Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Bevacizumab-based therapy in r ...... d clinical experience to date.
@en
type
label
Bevacizumab-based therapy in r ...... d clinical experience to date.
@en
prefLabel
Bevacizumab-based therapy in r ...... d clinical experience to date.
@en
P2860
P356
P1476
Bevacizumab-based therapy in r ...... d clinical experience to date.
@en
P2093
Olivier L Chinot
P2860
P304
P356
10.1586/ERA.12.128
P577
2012-11-01T00:00:00Z